Interim analysis from ORIENT-31 demonstrates a four-drug regimen may be a reasonable option for patients whose disease has progressed on EGFR TKIs. Read more
Finding precision treatments after molecular testing requires a tool for reviewing actionable mutations. Read more
Without validated biomarkers for anti-angiogenesis therapy, VEGF inhibitors are increasingly being investigated. Read more
Approval opens the door for an immunotherapy-based treatment option prior to surgery for the first time. Read more
Study tests combination of taxanes with an angiogenesis inhibitor in search for better outcomes for patients with advanced KRAS-mutated NSCLC. Read more
During an interview with ILCN, Drs. Paul Paik and Jonathan Reiss discuss the implications of KEAP1 and NFE2L2 mutations in NSCLC. Read more
Lung cancer specialists are slowly being faced with the challenge of how to balance the benefits of next-generation tumor tissue testing against those of liquid biopsy in the clinic. During […] Read more
See how specialists in France use MTBs to develop the most beneficial treatment strategies for patients and to decrease inequity in cancer care. Read more
Study findings suggest that a significant number of unplanned hospital visits for patients with lung cancer might be avoidable. Read more
Study shows emerging techniques may improve prognostic and predictive models in identifying patients at risk for early weight loss. Read more